{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-144582","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2026-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.848562+00:00","generated_at":"2026-05-15T07:03:42.802296+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Inhibikase enrolls first patient in Phase 3 PAH study of IKT-001","bullets":["First patient enrolled in global pivotal Phase 3 IMPROVE-PAH trial (NCT07365332).","Part A: ~140 patients, primary endpoint change in PVR at Week 24, double-blind placebo-controlled.","Part B: ~346 patients, primary endpoint change in 6MWD at Week 24, seamless transition from Part A.","Adaptive design includes a 12-week dose-titration phase; FDA confirmed study plan.","Trial to be conducted at up to ~180 sites worldwide; NDA filing timeline accelerated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-144582","json":"https://secwatch.observer/filing/0001193125-26-144582.json","markdown":"https://secwatch.observer/filing/0001193125-26-144582.md","text":"https://secwatch.observer/filing/0001193125-26-144582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526144582/0001193125-26-144582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526144582/d108350d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:03:42.802296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}